Chiara Bravetti

Body mass index in type 2 spinal muscular atrophy: a longitudinal study

M. Pane, E. Mercuri, A. D’Amico, 2022, European Journal of Pediatrics.

Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening

C. Palermo, M. Pane, E. Mercuri, 2022, European Journal of Pediatrics.

Nusinersen in type 1 spinal muscular atrophy: Twelve‐month real‐world data

E. Bertini, M. Pane, E. Mercuri, 2019, Annals of neurology.

Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients

E. Bertini, C. Palermo, M. Pane, 2021, Annals of clinical and translational neurology.

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy

C. Palermo, M. Pane, E. Mercuri, 2022, Annals of clinical and translational neurology.

Type I spinal muscular atrophy patients treated with nusinersen: 4‐year follow‐up of motor, respiratory and bulbar function

C. Palermo, M. Pane, A. D’Amico, 2023, European journal of neurology.

Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study

M. Pane, V. Sansone, M. Pera, 2023, Journal of clinical medicine.

Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies

S. Corti, R. Finkel, C. Palermo, 2023, EClinicalMedicine.